

KASHYAP TELE-MEDICINES LIMITED

CIN: L29110MH1995PLC085738

Regd. Off.: 2nd Floor, Pushpawati Building No. 2, Girgaon Road, Chandanwadi, Mumbai –400002

Corp. Off. : UL/8, Upper Floor, Suryarath Complex, Panchwati 1st Lane Ambawadi, Ahmedabad, Gujarat-380006

Phone: +91-6359637788, Email: investor.relations@kashyaptele-medicines.com,

Website: www.kashyaptele-medicines.com

Date: 27th July, 2022

To,
BSE Limited
Listing Department,
Phiroz Jeejeebhoy Tower,
25th Floor, Dalal Street,
Mumbai-400 001

Scrp Code – 531960

Sub.: Outcome of Board Meeting held on 27th July, 2022 as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.


Dear Sir/Madam,

With reference to above and as per intimation given for meeting of the Board of Directors, we are pleased to inform that above referred meeting was held on 27th July, 2022 wherein the Board of Directors, inter alia:

1. has considered and approved Unaudited Financial Results along with Limited Review Report thereon as received from the Statutory Auditors of the Company [M/s. Saremal & Company, (FRN: 109281W), Chartered Accountants, Ahmedabad] for the quarter ended on 30th June, 2022 as prepared in accordance with Regulation 33 of the SEBI (LODR) Regulations, 2015 and Schedule III of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules, 2015 (IND-AS).
2. on recommendation of Nomination & Remuneration Committee of the Company, has considered and approved re-appointment of Mr. Devkinandan Sharma as an Non-Executive Independent Director; subject to the approval for shareholders in this ensuing Annual General Meeting; for the 2nd consecutive term of 5 years; in accordance with provisions of Sections 149, 150, 152 read with Schedule IV and all other applicable provisions of the Companies Act, 2013 and the Companies (Appointment and Qualification of Directors) Rules, 2014 (including any statutory modification(s) or re-enactment thereof for the time being in force) and Regulation 17 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Further, Mr. Devkinandan Sharma is chairperson of Audit Committee and Nomination and Remuneration committee of the Company.

The brief particulars of Mr. Devkinandan Sharma as per the Regulation 30(2) & Para A of Part A of Schedule III of SEBI (LODR) Regulations, 2015 are detailed in the table below:

Reason of Change (Re-appointment)	Due to expiry of existing term on 11 th August, 2022. There being no other material reason for such change by way of re-appointment.
Effective Date of Re-Appointment & Term of Re-appointment	Re-Appointment for 2 nd consecutive term of 5 years i.e. w.e.f. 12 th August, 2022 to 11 th August, 2027 which shall not be liable to retire by rotation, and other terms as per the re-appointment letter which shall be issued subject to the approval of shareholders in the ensuing Annual General Meeting.
Brief Profile	Mr. Devkinandan Sharma, aged about 50 years is a Non-Executive Independent director of the Company. He is a commerce graduate and has completed his B.Com from Rajasthan University. He have a rich and varied experience in the areas such as Business Management, Strategic Planning, and Customer Engagement etc.
Relationship with Directors/KMP	Mr. Devkinandan Sharma is not related to any of the other Directors and Key Managerial Personnel of the Company.



KASHYAP TELE-MEDICINES LIMITED

CIN: L29110MH1995PLC085738

Regd. Off.: 2nd Floor, Pushpawati Building No. 2, Girgaon Road, Chandanwadi, Mumbai –400002

Corp. Off. : UL/8, Upper Floor, Suryarath Complex, Panchwati 1st Lane Ambawadi, Ahmedabad, Gujarat-380006

Phone: +91-6359637788, Email: investor.relations@kashyaptele-medicines.com,

Website: www.kashyaptele-medicines.com

Further, pursuant to SEBI Circular No LIST/COMP/14/2018-19 dated 20th June, 2018 and on the basis of due verification, the Company hereby ensures that Mr. Devkinandan Sharma being re-appointed is not been debarred from holding the office of Director by virtue of any order passed by SEBI or any such authority. Also, the Company has received the respective declaration in this regard from the said Director.

3. On recommendation of Audit Committee of the Company, has considered and approved re-appointment of M/s. Saremal & Company (FRN:109281W), Chartered Accountant, Ahmedabad; subject to the approval for shareholders in this ensuing Annual General Meeting; for 2nd consecutive term of 1 year; in accordance with section 139, 141, 142 and other applicable provisions, if any, of the Companies Act, 2013 and The Companies (Audit and Auditors) Rules, 2014.

Particulars as per the Regulation 30(2) & Part A of Schedule III of SEBI (LODR) Regulations, 2015;

Reason of Change viz. Re-Appointment	Due to Expiry of existing 1 st term of his appointment at the 28 th Annual General Meeting
Date of Re-Appointment & Term of Re-appointment	Re-Appointment for 2 nd consecutive term of 1 year i.e. from the conclusion of 28 th AGM till the conclusion of 29 th AGM and to conduct the statutory audit for the F.Y. 2022-2023 on such terms and conditions as may be agreed mutually between the said statutory auditors and the Board of Directors, subject to the approval for shareholders in this ensuing Annual General Meeting.
Brief Profile	M/s Saremal & Co. is a firm of Chartered Accountants situated at Ahmedabad, engaged in the profession of Financial and System Auditing, System Development Advisory services, Taxation, Financial and Investment Management, Investigation, Corporate Services; Management related services and Consultancy in Corporate and other allied laws since last 42 years. The firm is established in 1979 headed by its senior partner Shri S. P. Shah. The firm, since then, has been offering varied services to its clients. The firm is Peer Reviewed by ICAI and holds a valid Peer Review Certificate.

4. Considered and approved the date, time and mode of convening 28th Annual General Meeting of the Company, to be held on Tuesday, 23rd August, 2022 at 3.00 P.M. through Video Conferencing (VC)/Other Audio Visual means(OAVM) alongwith approval of Notice of AGM in that regard;
5. Considered and approved all other businesses as per agenda circulated.

The Meeting of the Board of Directors commenced at 3.00 p.m. and concluded at 6.55 p.m.

Kindly take the above disclosures on your record as compliance with Regulations 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

You are requested to take note of the same.

Thanking you.

Yours faithfully,

FOR, KASHYAP TELE-MEDICINES LIMITED

PARITOSH TRIVEDI
COMPANY SECRETARY



Encl: As above



SAREMAL & CO

Chartered Accountants

CA Saremal Shah (Bcom, FCA); CA Pravin Lavana (Bcom, LLB, FCA)

INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT ON THE QUARTERLY UNAUDITED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED 30TH JUNE, 2022 OF THE COMPANY PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015, AS AMENDED

To
The Board of Directors,
KASHYAP TELE-MEDICINES LIMITED
AHMEDABAD

1. We have reviewed the accompanying statement of Un-audited Financial Results of **M/S KASHYAP TELE-MEDICINES LIMITED** (the Company) for the first quarter ended 30th June, 2022 being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 as amended (the 'Listing Regulations'), read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016, SEBI Circular No. CIR/CFD/CMD1/44/2019 dated 29th March, 2019 and SEBI Circular No. CIR/CFD/CMD1/80/2019 dated 19th July, 2019. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review in accordance with the Statement on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our Conclusion is not modified in respect of this matter.



For SAREMAL & CO.
Chartered Accountants

Pravin Lavana
(Partner)

Membership NO.: 037180

Firm Registration NO.: 109281W

UDIN No. 22037180ANROOR4377

Ahmedabad, 27th July, 2022

KASHYAP TELE-MEDICINES LIMITED

CIN: L29110MH1995PLC085738

Regd. Off.: 2nd Floor, Pushpawati Building No. 2, Girgaon Road, Chandanwadi, Mumbai - 400002
 Corp. Off. : UL/8, Upper Floor, Suryarath Complex, Panchwati 1st Lane Ambawadi, Ahmedabad, Gujarat-380006
 Phone: +91-6359637788, Email: investor.relations@kashyaptele-medicines.com
 Website: www.kashyaptele-medicines.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED 30TH JUNE, 2022

(As per Regulation 33 of SEBI (LODR) Regulations, 2015 & Schedule III Companies Act, 2013 read with IND-AS)

S.No.	Particulars	Amount (Rs.) in Lakhs Except EPS			
		Quarter Ended			Year ended
		30/06/2022	31/03/2022	30/06/2021	31/03/2022
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
I	Revenue from operations	5.30	4.00	5.00	19.55
II	Other Income	0.00	0.00	0.00	0.00
III	Total Revenue (I + II)	5.30	4.00	5.00	19.55
IV	Expenses				
	(a) Cost of materials consumed	0.00	0.00	0.00	0.00
	(b) Purchases of stock-in-trade	0.00	0.00	0.00	0.00
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.00	0.00	0.00	0.00
	(d) Employee benefits expense	2.55	2.30	2.21	9.27
	(e) Finance Cost	0.00	0.00	0.00	0.00
	(f) Depreciation and amortisation expense	0.00	0.00	0.00	0.00
	(g) Other expenses	1.98	14.85	1.89	20.69
	Total expenses	4.53	17.15	4.10	29.96
V	Profit/(Loss) before exceptional and extraordinary items and tax (III-IV)	0.77	(13.15)	0.90	(10.41)
VI	Exceptional items	0.00	(162.46)	0.00	(162.46)
VII	Profit before extraordinary items and tax (V - VI)	0.77	(175.61)	0.90	(172.87)
VIII	Extraordinary items	0.00	0.00	0.00	0.00
IX	Profit/(Loss) Before Tax (VII- VIII)	0.77	(175.61)	0.90	(172.87)
X	Tax expense :-				
	(a) Current tax	0.19	(0.63)	0.21	0.00
	(b) Tax relating to previous year	0.00	(0.11)	0.00	(0.11)
	(c) Deferred tax	0.00	0.00	0.00	0.00
	Total Tax Expense	0.19	(0.74)	0.21	(0.11)
XI	Profit / (Loss) for the period from continuing operations (IX - X)	0.58	(174.87)	0.69	(172.76)
XII	Profit/(loss) from discontinuing operations	0.00	0.00	0.00	0.00
XIII	Tax expense of discontinuing operations	0.00	0.00	0.00	0.00
XIV	Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)	0.00	0.00	0.00	0.00
XV	Profit / (Loss) for the period (XI + XIV)	0.58	(174.87)	0.69	(172.76)
XVI	Share of profit / (loss) of Associates	N.A.	N.A.	N.A.	N.A.
XVII	Minority interest	N.A.	N.A.	N.A.	N.A.
XVIII	Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates	0.58	(174.87)	0.69	(172.76)
XIX	Other Comprehensive Income				
	A. Items that will be/will not be reclassified to profit and loss	0.00	0.00	0.00	0.00
	B. Income tax relating to items that will be / will not be reclassified to profit and loss	0.00	0.00	0.00	0.00
XX	Total comprehensive income for the period (XVIII+XIX)	0.58	(174.87)	0.69	(172.76)
XXI	Paid-up equity share capital (Face Value of Rs. 1/- each)	477.22	477.22	477.22	477.22
XXII	Earnings per equity share:				
	(a) Basic	0.001	(0.366)	0.001	(0.362)
	(b) Diluted	0.001	(0.366)	0.001	(0.362)

Notes:

- The above Unaudited Financial Results of the company for the quarter ended on 30th June, 2022 have been reviewed by the Audit Committee and approved by the Board of Directors in the Meeting held on 27th July, 2022.
- The Company has adopted, Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ('Ind As') from 1st April, 2017 and accordingly these financial results and all the periods presented have been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 "Interim Financial Reporting" read with relevant rules issued thereunder and the other accounting principles generally accepted in India and discloses the information required to be disclosed in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015 (as amended).
- The Statutory Auditors of the Company have carried out Limited Review of the above Unaudited Financial Results for the quarter ended on 30th June, 2022 in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.
- A Copy of the aforesaid financial results is also available on the website of BSE Limited (www.bseindia.com) and on the website of the Company (www.kashyaptele-medicines.com).
- The company is engaged in single segment therefore has only one reportable segment in accordance with Ind AS 108 'Operating Segments'.
- Figures pertaining to previous year/periods have been re-grouped and re-arranged wherever necessary.

Place : Ahmedabad
 Date : 27th July, 2022



For and on behalf of Board of Directors of
 Kashyap Tele - Medicines Limited



Amit Agarwal
 Managing Director
 DIN: 00169061